Hematology and Oncology

I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with ...

Cancer immunology and immunotherapy. The Zhang laboratory functions as an integrated translational research program with the goal of designing and developing new immunotherapies and immunologic strategies for cancer treatment. The ongoing projects are focused on dissecting the molecular mechanisms used for tumor immune evasion based on the cutting-edge technical platforms.

Personalized Cancer Therapy, Precision Medicine, Early Phase Clinical Trials, First-in-Human Study, Novel Combination Cancer Therapy, Targeted therapy, Immunotherapy, Biomarker Study, Novel Drug Development, Novel Drug Delivery System, Adaptive Clinical Trials Design, Cell Signaling Pathway, Immune Checkpoint Pathway

Judith Paice, PhD, RN is the Director of the Cancer Pain Program in the Division of Hematology-Oncology and a Research Professor of Medicine, Northwestern University; Feinberg School of Medicine. She is also a full member of the Robert H. Lurie Comprehensive Cancer Center. Dr. Paice has served as President of the American Pain Society and Secretary of the International Association for the Study of Pain. Much of Dr Paice’s clinical work has been in the relief of pain associated with cancer and HIV disease. She has traveled widely within the People’s Republic of China, Indonesia, Japan, Kenya, K...

My clinical domain is breast cancer management. My clinical research interest focuses on the development of novel therapies for the treatment of breast cancer. Clinical trials focusing on precision medicine for defining the right therapy, for the right patient at the right time is our goal. To that end, molecular interogation of breast tumors are leading to novel trial design that will hopefully translate into better outcomes for our patients. In conjuction with the developmental therapeutics program, novel agents are being incorporated into clinical trials for patients with both early and lat...

The overarching goal of my involvement in translational research is to improve the outcome of patients with lymphoma. With scientists in the US and abroad, we are currently investigating novel signaling pathways in lymphoma, using cell lines and animal model systems. More specifically, our research focuses on the biology of reactive oxygen species signaling pathways in lymphoma. Active investigations include: 1) the biology of the lactone diterpenoids in lymphoma; 2) the development of all trans retinoic acid (ATRA) and curcumin loaded nanodisks as a drug delivery vehicle in mantle cell lympho...

Colon cancer, Gastric cancer, Pancreas cancer, Rectal cancer

Immunotherapy strategies for treatment of melanoma, renal cell cancer, other urologic tumors and Mycosis fungoides